Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats

Diabetes, Obesity and Metabolism

Volumn 14, Issue 7, 2012, Pages 644-653

  Huang, J ^a   Li, X ^b   Li, M ^a   Li, S ^a   Xiao, W ^a   Chen, X ^a   Cai, M ^a   Wu, Q ^c   Luo, D ^c   Tang, S ^a   Luo, Y ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Chengdu Kanghong Biotechnology Co Ltd   (China)

Author keywords

Diabetic retinopathy; Inner blood retinal barrier; KH902; Placental growth factor; Retinal electrophysiological function; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CLAUDIN 5; EVANS BLUE; HYBRID PROTEIN; KH 902; KH902; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; PROTEIN KINASE B; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RETINA BARRIER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OPHTHALMOLOGY; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

EID: 84862790804     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01584.x     Document Type: Article

References (49)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376: 124-136.
2. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-455.
3. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57: 1026-1033.
4. Beck RW, Edwards AR, Aiello LP et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-251.
5. Arevalo JF, Sanchez JG, Lasave AF et al. Intravitreal bevacizumab (Avastin(R)) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture. Curr Diabetes Rev 2010; 6: 313-322.
6. Waisbourd M, Goldstein M, Loewenstein A. Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol 2010.
7. Gulkilik G, Taskapili M, Kocabora S, Muftuoglu G, Demirci G. Intravitreal bevacizumab for persistent macular edema with proliferative diabetic retinopathy. Int Ophthalmol 2010; 30: 697-702.
8. Porta M, Maldari P, Mazzaglia F. New approaches to the treatment of diabetic retinopathy. Diabetes Obes Metab 2011; 13: 784-790.
9. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 915-930.
10. Nguyen QD, Shah SM, Browning DJ et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 2141-2148.
11. Cunningham ET Jr, Adamis AP, Altaweel M et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
12. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398.
13. Zhang M, Zhang J, Yan M et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011; 118: 672-678.
14. Le XF, Mao W, Lu C et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 2008; 7: 3747-3758.
15. Qaum T, Xu Q, Joussen AM et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42: 2408-2413.
16. Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 2008; 14: 37-49.
17. Zhang M, Yu D, Yang C et al. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009; 26: 204-210.
18. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol 2009; 247: 171-177.
19. Yu L, Wu X, Cheng Z et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49: 522-527.
20. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci 2010; 51: 4569-4573.
21. Hoffart L, Matonti F, Conrath J et al. Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clin Experiment Ophthalmol 2010; 38: 346-352.
22. Ma J, Zhu T, Tang X, Ye P, Zhang Z. Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. Clin Experiment Ophthalmol 2010; 38: 875-884.
23. Hashemian MN, ZM H, Moghimi S, Tahvildari M, Mojazi-Amiri H. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Ophthalmic Res 2011; 46: 50-54.
24. Koto T, Takubo K, Ishida S et al. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 2007; 170: 1389-1397.
25. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res 2002; 74: 615-625.
26. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev 1995; 11: 109-120.
27. Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol 1999; 44: 53-60.
28. Du ZJ, Kamei M, Suzuki M, Tano Y, Wang BR, Hui YN. Coordinated expression of Ets-1, pERK1/2, and VEGF in retina of streptozotocin-induced diabetic rats. Ophthalmic Res 2007; 39: 224-231.
29. Bucolo C, Ward KW, Mazzon E, Cuzzocrea S, Drago F. Protective effects of a coumarin derivative in diabetic rats. Invest Ophthalmol Vis Sci 2009; 50: 3846-3852.
30. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 283-290.
31. Lieth E, Gardner TW, Barber AJ, Antonetti DA. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 2000; 28: 3-8.
32. Zakareia FA, Alderees AA, Al Regaiy KA, Alrouq FA. Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy. J Diabetes Complications 2010; 24: 179-185.
33. Yasuda S, Kachi S, Kondo M et al. Significant correlation between electroretinogram parameters and ocular vascular endothelial growth factor concentration in central retinal vein occlusion eyes. Invest Ophthalmol Vis Sci 2011; 52: 5737-5742.
34. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2007; 48: 5152-5159.
35. Yoshida Y, Yamagishi S, Matsui T et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev 2009; 25: 678-686.
36. D'Amore PA. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol 2007; 171: 14-18.
37. Kowalczuk L, Touchard E, Omri S et al. Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One 2011; 6: e17462.
38. Akrami H, Soheili ZS, Sadeghizadeh M et al. PlGF gene knockdown in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2010.
39. Cao R, Xue Y, Hedlund EM et al. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci USA 2010; 107: 856-861.
40. Khaliq A, Foreman D, Ahmed A et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Laboratory investigation; a journal of technical methods and pathology 1998; 78: 109-116.
41. Autiero M, Waltenberger J, Communi D et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
42. Zhao B, Cai J, Boulton M. Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2. Microvasc Res 2004; 68: 239-246.
43. Valiatti FB, Crispim D, Benfica C, Valiatti BB, Kramer CK, Canani LH. The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy. Arq Bras Endocrinol Metabol 2011; 55: 106-113.
44. Odorisio T, Schietroma C, Zaccaria ML et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002; 115: 2559-2567.
45. Leal EC, Martins J, Voabil P et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. Diabetes 2010; 59: 2637-2645.
46. Klaassen I, Hughes JM, Vogels IM, Schalkwijk CG, Van Noorden CJ, Schlingemann RO. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes. Exp Eye Res 2009; 89: 4-15.
47. Huang Q, Sheibani N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol 2008; 295: C1647-1657.
48. Ye X, Xu G, Chang Q et al. ERK1/2 signaling pathways involved in VEGF release in diabetic rat retina. Invest Ophthalmol Vis Sci 2010; 51: 5226-5233.
49. Zhang Q, Wang D, Kundumani-Sridharan V et al. PLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization. Blood 2010; 116: 1377-1385.